Jerini
1984
FOUNDED
M&A
STATUS
101-200
EMPLOYEES
M&A
LATEST DEAL TYPE
$551M
LATEST DEAL AMOUNT
Description
Developer and marketer of peptide-based drugs. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema. Its developing product pipeline includes JSM 6427, a a5ß1 Integrin antagonist for the treatment of cancer, age-related mascular degeneration-blindness in the elderly, and angiogenesis, inflammation, and fibrosis; and JSM-7717 and JPE-1375, which are C5a receptor antagonists for the treatment of inflammatory and ophthalmological diseases.
Primary Office
- Invalidenstrasse 130
- 10115 Berlin
- Germany
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Jerini’s full profile, request a free trial.
Jerini Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 03-Jul-2008 | $551M | 00000 | 00000 | Completed | Generating Revenue |
| 3. IPO | 01-Nov-2005 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 09-Jun-2004 | $37.7M | $43.1M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | $5.48M | $5.48M | Completed |
Jerini Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Edelman Financial Services | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| HealthCap | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| IBB Beteiligungsgesellschaft | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| KfW Group | Investment Bank | Minority | 000 0000 | 000000 0 |